vs 6,490 other HR bills in the 111th — cohort avg 44d
Summary
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
Lobbying filings that explicitly cite this bill (29)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Cited source text, amounts, lobbyists, and targets
H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009
S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and
related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Client expense: $70,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 930/S. 571- Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; Comments Regarding Implementation of Biologics Price Competition and Innovation Act.
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Client expense: $70,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009
S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and
related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Client expense: $70,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Cited source text, amounts, lobbyists, and targets
H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009
S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and
related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Cited source text, amounts, lobbyists, and targets
H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009
S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 930: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; S. 571: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; HIT funding; H.R. 3200: America's Affordable Health Choice Act of 2009; S. 1679: Affordable Health Choice Act; America's Healthy Future Act; Patient Protection & Affordable Care Act (H.R. 3590/Pub.L.No.111-148) and Affordable Health Care for America America (H.R. 3962).
Client expense: Not reported · Firm income: $40,000
Cited source text, amounts, lobbyists, and targets
H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009
S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 930: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; S. 571: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; H.R. 1 American Recovery and Reinvestment Act of 2009 (P.L. 111-5); HIT funding; H.R. 3200: America's Affordable Health Choice Act of 2009; S. 1679: Affordable Health Choice Act; America's Healthy Future Act; Patient Protection & Affordable Care Act (H.R. 3590) and Affordable Healthcare for America (H.R. 3962).
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 930: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009
S. 571: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Cited source text, amounts, lobbyists, and targets
H.R. 930: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; S. 571: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; H.R. 1 American Recovery and Reinvestment Act of 2009 (P.L. 111-5); HIT funding; H.R. 3200: America's Affordable Health Choice Act of 2009; S. 1679: Affordable Health Choice Act; America's Healthy Future Act.
Client expense: Not reported · Firm income: $60,000
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Cited source text, amounts, lobbyists, and targets
H.R. 930, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009
S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis .
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis , including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Cited source text, amounts, lobbyists, and targets
H.R. 930: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; S. 571: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009; H.R. 1 American Recovery adn Reinvestment Act of 2009 (P.L. 111-5); HIT funding; Healthcare reform.
Client expense: Not reported · Firm income: $60,000
Cited source text, amounts, lobbyists, and targets
Access to care for people with psoriasis and psoriatic arthritis
H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 H.R. 930 and S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDICINE.
(a) In General- The Secretary shall enter into an agreement with the Institute of Medicine to conduct a study on the following:
(1) The extent to which public and private insurers cover prescription medications and other treatments for psoriasis and psoriatic arthritis.
(2) The payment structures, such as deductibles and co-payments, and the amounts and duration of coverage under health plans and their adequacy to cover the costs of providing ongoing care to, and ensure access for, patients with psoriasis and psoriatic arthritis.
(3) Health plan and insurer coverage policies and practices, including lifetime caps, and their impact on the access of such patients to the best regimen and most appropriate care for their particular disease state.
(b) Report- The agreement entered into under subsection (a) shall provide for the Institute of Medicine to submit to the Secretary and the Congress, not later than 18 months after the date of the enactment of this Act, a report containing a description of--
(1) the results of the study conducted under this section; and
(2) the conclusions and recommendations of the Institutes of Medicine regarding each of the issues described in paragraphs (1) through (3) of subsection (a).
Cited source text, amounts, lobbyists, and targets
H.R. 930, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009
S. 571, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009 SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH.
(a) In General- The Secretary of Health and Human Services (in this Act referred to as the `Secretary'), acting through the Director of the National Institutes of Health, shall continue to expand and intensify research and related activities of the Institutes with respect to psoriasis and psoriatic arthritis.
(b) Research by National Institute of Arthritis and Musculoskeletal and Skin Diseases-
(1) IN GENERAL- The directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall continue to conduct and support research to expand understanding of the causes of, and to find a cure for, psoriasis and psoriatic arthritis, including the following:
(A) Basic research to discover the pathogenesis and pathophysiology of the disease.
(B) Expansion of molecular biology and immunology studies, including additional animal models.
(C) Global association mapping with single nucleotide polymorphisms.
(D) Identification of environmental triggers and autoantigens in psoriasis.
(E) Elucidation of specific immunologic cells and their products involved.
(F) Pharmacogenetic studies to understand the molecular basis for varying patient response to treatment.
(G) Identification of genetic markers of psoriatic arthritis susceptibility.
(H) Research to increase understanding of joint inflammation and destruction in psoriatic arthritis.
(I) Investigator-initiated clinical research for the development and evaluation of new treatments, including new biological agents.
(J) Research to develop enhanced diagnostic tests that allow for earlier diagnosis of psoriasis and improved outcomes.
(K) Research to increase understanding of the epidemiology and pathophysiology of co-morbidities associated with psoriasis, including shared molecular pathways.
(2) COORDINATION WITH OTHER INSTITUTES- In carrying out paragraph (1), the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Allergy and Infectious Diseases shall coordinate the activities of such Institutes with the activities of other national research institutes and other agencies and offices of the National Institutes of Health relating to psoriasis or psoriatic arthritis.
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION AND NATIONAL PATIENT REGISTRY.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention and in collaboration with a national organization serving people with psoriasis and psoriatic arthritis, shall undertake psoriasis and psoriatic arthritis data collection and develop a psoriasis and psoriatic arthritis patient registry.
SEC. 6. NATIONAL SUMMIT.
(a) In General- Not later than one year after the date of the enactment of this Act, the Secretary is encouraged to convene a summit on the Federal Government's current and future efforts, and the initiatives necessary to fill any gaps, with respect to the conduct or support of psoriasis and psoriatic arthritis research, treatment, education, quality-of-life, and data collection activities. The summit should also address psoriasis and psoriatic arthritis related co-morbidities and should include researchers, public health professionals, representatives of voluntary health agencies and patient advocacy organizations, representatives of academic institutions, representatives from the pharmaceutical and medical research industry, and Federal and State policymakers, including representatives of the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, the Food and Drug Administration, and the National Institutes of Health.
(b) Focus- The summit convened under this section should focus on--
(1) a broad range of research activities relating to biomedical, epidemiological, psychosocial, and rehabilitative issues;
(2) clinical research for the development and evaluation of new treatments, including new biological agents;
(3) translational research;
(4) information and education programs for health care professionals and the public;
(5) priorities among the programs and activities of the various Federal agencies involved in psoriasis and psoriatic arthritis and related co-morbidities; and
(6) challenges, opportunities, and recommendations for scientists, clinicians, patients, and voluntary organizations.
(c) Report to Congress- Not later than 180 days after the first day of the summit convened under this section, the Secretary shall submit to the Congress and make publicly available a report that includes a description of--
(1) the proceedings at the summit; and
(2) recommendations related to the research, treatment, education, and quality-of-life activities conducted or supported by the Federal Government with respect to psoriasis and psoriatic arthritis, including psoriasis and psoriatic arthritis related co-morbidities.
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 930: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009
S. 571: Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2009
HIT funding in Stimulus
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Client expense: $120,000 · Firm income: Not reported